A company called Xenetic Biosciences, Inc. that does clinical-stage biopharmaceutical discovery, research and development. They focus on orphan oncology therapeutics. The plans to acquire the XCART platform, a technology engineered to target personalized, patient-specific tumor neoantigens was in the works. The Company is looking toward the treatment of B-cell lymphomas. Hmm? Interesting.